The ANZUP Cancer Trials Group reported the results of TheraP, a phase II open-label, randomized, multicenter trial that enrolled metastatic-castrate-resistant prostate cancer (mCRPC) patients, aiming to determine the activity and safety of [177Lu]Lu-PSMA compared to cabazitaxel in men with progressive mCRPC previously treated with docetaxel (NCT03392428) [29]. This evidence concerns the gene FOLH1 and cancer.